News Novartis' Zykadia gets fast first-line lung cancer review Roche rival has Breakthrough Therapy status.
News Roche’s Alecensa approved in Europe, with head-to-head data ... Alecensa part of Roche's goal of becoming dominant player in NSCLC
News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
News Can Keytruda beat Opdivo to full UK access in lung cancer? A decisive moment in lung cancer treatment is nearing
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.